Deletion of P2Y2 receptor reveals a role for lymphotoxin-α in fatty streak formation by Aian, Shaomin et al.
Vascular Pharmacology 85 (2016) 11–20
Contents lists available at ScienceDirect
Vascular Pharmacology
j ourna l homepage: www.e lsev ie r .com/ locate /vphDeletion of P2Y2 receptor reveals a role for lymphotoxin-α in fatty
streak formation☆Shaomin Qian a, April Hoggatt a, Yava L. Jones-Hall b, Carl F. Ware c, Paul Herring a, Cheikh I. Seye a,⁎
a Department of Cellular & Integrative Physiology, Indiana University School of Medicine, 635 Barnhill Drive MS 332, Indianapolis, IN 46202, United States
b Department of Comparative Pathobiology, Purdue University, College of Veterinary Medicine, 725 Harrison Street VPTH 124, West Lafayette, IN 47907-2027, United States
c Sanford-Burnham Medical Institute, La Jolla, CA 92037, United States☆ Funding sources: This work was supported by a gran
Health (1R01HL112883) to Cheikh I. Seye.
⁎ Corresponding author.
E-mail address: cseye@iu.edu (C.I. Seye).
http://dx.doi.org/10.1016/j.vph.2016.06.001
1537-1891/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 7 March 2016
Received in revised form 2 May 2016
Accepted 2 June 2016
Available online 26 June 2016Background: Lymphotoxin alpha (LTα) is expressed inhuman atherosclerotic lesions and genetic variations in the
LTα pathway have been linked tomyocardial infarction. Activation of the P2Y2 nucleotide receptor (P2Y2R) reg-
ulates the production of LTα. in vitro. We aimed to uncover a potential pathway linking purinergic receptor to
LTα-mediated inﬂammatory processes pivotal to the early stages of atherosclerosis in apolipoprotein E
(ApoE−/−) deﬁcient mice.
Methods and results: En face immunostaining revealed that P2Y2R andVCAM-1 are preferentially expressed in the
atherosclerosis prone site of the mouse aortic sinus. Deletion of the P2Y2R gene suppresses VCAM-1 expression.
Comparedwith ApoE−/−mice, ApoE−/−mice lacking the P2Y2R gene (ApoE
−/−/P2Y2R
−/−) did not develop fatty
streak lesions when fed a standard chow diet for 15 weeks. Systemic and CD4+ T cell production of the pro-
inﬂammatory cytokine lymphotoxin-alpha (LTα) were speciﬁcally inhibited in ApoE−/−/P2Y2R−/−mice. Anti-
LTα preventive treatment was initiated in ApoE−/−mice with intraperitoneal administration of recombinant
human tumor necrosis factor receptor 1 fusion protein (TNFR1-Fc) on 5 consecutive days before the disease
onset. Remarkably, none of the TNFR1:Fc-treated ApoE−/−mice exhibited atherosclerotic lesions at any develop-
mental stage.
Signiﬁcance: ApoE−/−mice deﬁcient in P2Y2R exhibit low endothelial cell VCAM-1 levels, decreased production
of LTα and delayedonset of atherosclerosis. These data suggest that targeting this nucleotide receptor could be an
effective therapeutic approach in atherosclerosis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerosis is widely considered to be an inﬂammatory disease
involving the recruitment of leukocytes, and the activation of pro-
thrombotic pathways [1]. Targeted control of pro-inﬂammatory factors
that have the potential to support endothelial dysfunction could have a
signiﬁcant impact on the limitation of vascular complications. The car-
diovascular purinergic signaling system is a promising source for
novel drug targets. Clinical trials have provided clear evidence that
purinergic antithrombotic drugs reduce the risks of recurrent strokes
and heart attacks [2–3]. These drugs are antagonists to the P2Y12 recep-
tor that mediates platelet aggregation [4].
Leukocyte adherence to the endothelium in lesion-prone areas of
the arterial wall is one of the earliest cellular responses in the formationt from the National Institute of
. This is an open access article underof lesions of atherosclerosis [5]. Vascular cell adhesion molecule-1
(VCAM-1) is particularly important for ﬁrm, integrin-mediated
adhesion of leukocyte to endothelial cells (EC) and subsequent trans-
endothelial migration [6]. Under traumatic arterial events, nucleotide
release activates a speciﬁc nucleotide receptor subtype, the P2Y2R, lead-
ing to the transmigration of blood-derived cells into the vessel wall and
subsequent development of intimal hyperplasia [7]. Comparison of sig-
nal transduction pathways for wild type and different mutant P2Y2R
constructs have identiﬁed structural features that enable the P2Y2R to
regulate VCAM-1 expression on ECs [8].
Stimulation of P2 receptors is coupled to the release of pro-
inﬂammatory cytokines [9–12] that are of obvious relevance to the de-
velopment of atherosclerosis. In particular, activation of the P2Y2R has
been shown to regulate the production lymphotoxin alpha (LTα) in
macrophages [13]. LTα is a member of the TNF ligand family and is
synthesized predominantly by activated T-and B-lymphocytes [14].
Genetic variations in the LTα pathway have been linked to myocardial
infarction [15]. Because these ﬁndings imply a role for P2Y2R in vascular
inﬂammation, we investigated its contribution to the early stages ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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signal pathways linked to the activation of this nucleotide receptor de-
lays the onset of atherosclerosis in mice.
Our data show that deletion of the P2Y2R genemodulates inﬂamma-
tory processes pivotal to the development of early stage atherosclerosis,
thus limiting atherosclerotic plaque formation in ApoE−/− mice. This
conclusion is supported by evidence showing that loss of P2Y2R re-
presses VCAM-1 expression in the lesion prone site of the aortic sinus,
and selectively inhibits the production of the pro-inﬂammatory cyto-
kine LTα.
Subsequently, we showed that short-term treatment with soluble
recombinant human LTα antagonist inhibits fatty streak formation in
ApoE-deﬁcient mice.
This work deﬁnes a new pathway linking purinergic receptors to
LTα-mediated inﬂammatory processes pivotal to the development of
atherosclerosis.2. Materials and methods
2.1. Animals
Animal protocols were approved by the Animal Care and Use Com-
mittee of Indiana University. C57BL/6, ApoE−/− and P2Y2R−/− mice
were purchased from Jackson laboratory. P2Y2R−/−mice were bred to
the ApoE−/− background to generate ApoE−/−/P2Y2R−/−mice. All ani-
malwere fedwith a standard chowdiet. Onlymaleswere used in exper-
imental groups. Recombinant human TNFR1:Fc (100 μg per mouse per
day, n= at least 12mice per group)was administered intraperitoneally
on 5 consecutive days beginning at 5 weeks of age. For control, PBS or
100 μg of an irrelevant human IgG was used. Following treatment,
mice were maintained on standard chow diet until sacriﬁce at week 15.2.2. Antibody production
A rabbit polyclonal anti-P2Y2 receptor antibodies were
raised against a keyhole limpet hemocyanin-conjugated peptide
(NRTVRKDLSVSSDD) corresponding to amino acids 342–355 of
the mouse P2Y2R amino acid sequence (NM_01302347). Peptide
synthesis, animal immunization, and sera collections were per-
formed by Genscript (Piscataway, NJ). The antibodies were puriﬁed
by afﬁnity chromatography using an antigen peptide-conjugated
column.
The validity of the newly developed P2Y2R polyclonal antibody was
tested by immunohistochemistry on cross sections of aortic sinus sam-
ples fromwild-type and P2Y2R−/−mice. As shown in the Online ﬁgure,
both endothelial cells and smooth muscle cells in wild-type mice
expressed P2Y2R. In contrast, no P2Y2R-positive stainingwas detectable
in either cell type, thus conﬁrming the speciﬁcity of this antibody.2.3. Histological analysis and quantiﬁcation of aortic sinus lesions
Mouse hearts (n = 12 at least) were perfused, ﬁxed in 4% parafor-
maldehyde and embedded in parafﬁn. Sections were made and
discarded until the valve cups became visible. At that point, 5-μm sec-
tions were then collected and stained withMasson's Trichrome to iden-
tify collagen and muscle ﬁbers. The lesions were classiﬁed into ﬁve
different categories as previously described [16] to examine if there
were any differences in lesion severity.
For the quantiﬁcation of atherosclerotic lesions, hearts were embed-
ded in OCT and frozen sectionswere stainedwith Oil RedO. The relative
lesion area was calculated by dividing the lesion area by the total cross-
sectional area. The lesion area was measured with image analysis
(MetaMorph software, Universal Imaging Corp, Downingtown, Pa).2.4. Immunohistochemical analysis of aortic sinus lesions
Immunohistochemical staining was performed by the labeled
streptavidin biotin method. A rabbit polyclonal antibody against
human smooth muscle α-actin was used to detect smooth muscle
cells (Sigma, 1/1000 dilution). VCAM-1 immunostainingwas performed
on frozen sections with a rat anti-mouse VCAM-1 monoclonal antibody
(BD Pharmingen; 1/200 dilution). Macrophages were identiﬁed by
immunostaining with a rat anti-mouse Mac-3 monoclonal antibody
(M3/84, 550292, BD PharMingen, San Diego, CA; 1/100 dilution).
2.5. Lymphocyte preparation and cytokine analysis
Puriﬁed CD4+ cells were obtained from single cell suspensions
of splenocytes by negative selection using the EasySep™ Mouse
CD4+ T Cell Isolation Kit (StemCell Technologies). CD4+ T cells
(1 × 106/ml) were cultured in 48-well culture plates in 0.5 ml of RPMI
1640 medium containing 10% fetal calf serum, 5 mmol/L-glutamine,
50 IU penicillin G, and 50 μg streptomycin and were stimulated with
5 μg/ml plate- bound anti-CD3 mAb (BD Biosciences, San Diego, CA)
for 1–3 days. Concentrations of LTα in CD4+ T cell supernatant
or mouse blood plasma were determined with ELISA using a kit
(#MBS266789, BioSource).
2.6. Real-time polymerase chain reaction
Total RNA was extracted from aortic sinus samples using
RNeasymini kit (Qiagen). High quality RNA extracted was used for syn-
thesis of single-strand cDNA with Superscript II (Invitrogen). Real time
PCR was conducted with 45 ng of cDNA using an ABI Prism 7900HT
PCR machine (Applied Biosystems). The sequences of PCR primers
for VCAM-1 were 5′-CATGGAATTCGAACCCAAACA-30 (sense) and 5′-
GGCTGACCAAGACGGTTGTATC-3′ (anti-sense) as described elsewhere
(15). The following primer sequences were used for cytokines
mRNA ampliﬁcation: TNF-α-5′-ATGAGCACAGAAAGCATGATCCGCGAC-
3′ (sense), 5′- TCACAGAGCAATGACTCCAAAGTAGACCTG-3′ (antisense);
TNF-β-5′- CCCATGGCATCCTGAAAC-3′ (sense), 5′- GGAGGCCTGGAA
TCCAAT-3′ (antisense).
The PCR primer sequences for GAPDH were 5′-TGACG
TGCCGCCTGGAGAAAC-3′ (sense) and 5′-CCGGCATCGAAGGT GGAAG
AGT-3′ (anti-sense).
2.7. En face immunoﬂuorescent analysis of VCAM-1 expression
Aortic tissue segments were opened longitudinally and incubated
with PBS-T containing 10% donkey serum. Tissue segments were then
rinsed 3 times with PBS-T and incubated overnight at 4 °C with anti-
mouse VCAM-1 polyclonal antibodies (Santa Cruz Biotechnology Inc;
1:100) diluted in PBS-T. Anti-donkey secondary antibody labeled with
Alexa Fluor ﬂuorophoremolecules (Molecular Probes Inc.)was then ap-
plied for 45 min at room temperature. The segments were mounted on
slides, covered with Vectorshield mounting medium (Vector Laborato-
ries Inc) and observed with a FV1000 confocal system (Olympus). At
least 4 animals were used. Five pictures of each ﬁeld were captured at
different focal lengths and VCAM-1 positive cells per 1000 endothelial
cells were counted.
2.8. Promoter reporter assay
Murine VCAM-1 promoter sequence has been documented [17] and
is available on NCBI (accession number U42327). Genomic DNA was
obtained from C57BL/6 mice. The VCAM-1 promoter was ampliﬁed by
PCR as previously described [18] and cloned into the pGL3-Basic vector
(Promega) containing Fireﬂy luciferase reporter gene. The resultant
construct was co-transfected with the pRL-TK Vector (Promega) con-
taining Renilla luciferase reporter gene into the cultured ECs. A
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Gaithersburg, MD) were used for transfection of primary ECs according
to the instructions of themanufacturer. Transfected ECs were ﬁrst incu-
bated with or without the addition of UTP. Transfected cells were then
lysed, and the Fireﬂy-to-Renilla luciferase activity ratios in the lysates
were measured with dual-luciferase assay kit (Promega) for evaluation
of VCAM-1 gene promoter activity. Five independent experiments in
duplicates were performed.2.9. Cell culture
Mouse aortic ECs were isolated and cultured as described previously
[19]. Brieﬂy, aortas cut into circular rings were opened longitudinally
and placed luminal side down onto collagen gels. After 10 days, aortic
segmentswere removed, and collagen gelswere digestedwith 0.3% col-
lagenase H. ECs were grown in complete medium and used at passages
2 to 4.Fig. 1. Differential expression of VCAM-1 in regions of the mouse aorta. A, representative en fac
nuclei and VCAM-1 are in blue and green, respectively. Scale bar, 20 μm. P b 0.05. n=15 visual ﬁ
descending thoracic aorta of wild-type mice. Graphs show that the number of cells expressing
aorta. Endothelial cells incubated with only a second antibody were used as controls.2.10. Statistical analysis
All results are expressed as mean ± SEM. Differences between the
values of P b 0.05 were considered signiﬁcant with 2-tailed Student
t test.3. Results
3.1. P2Y2 receptor is preferentially expressed in atherosclerosis susceptible
region of the aorta
We conﬁrmed previous studies that show that VCAM-1 is preferen-
tially expressed in endothelial cells at lesion-prone sites [20]. As demon-
strated by en face immunostaining, VCAM-1 was abundantly expressed
in sinus aortic ECs of wild-type mice (Fig. 1A). In contrast, VCAM-1 was
not detected in the descending thoracic aorta (Fig. 1A). Flow cytometry
substantiated these results by demonstrating that the number of cellse immunostaining for VCAM-1 expression in the aorta of wild-type mice. Endothelial cell
elds. B, Flow cytometry analysis of EC surface expression of VCAM-1 in the aortic sinus and
VCAM-1 on the cell surface was greater in the aortic sinus as compared to the descending
14 S. Qian et al. / Vascular Pharmacology 85 (2016) 11–20expressing surface VCAM-1 was higher in aortic sinus ECs as compared
with ECs from the descending thoracic aorta (Fig. 1B). As P2Y2R
expressed in the vascular endothelium is known to regulate VCAM-1
expression [8,21], we examined the spatial distribution of P2Y2R in the
mouse aorta using a newly developed antibody. En face immunostain-
ing showed that P2Y2R was abundantly expressed in ECs at the curva-
ture of the aortic arch as compared to a more modest expression
found in the region of the descending thoracic aorta (Fig. 2A-B). These
results indicate P2Y2R is highly expressed in the VCAM-1 enriched
atherosclerosis prone-region of the aorta.3.2. P2Y2 receptor gene deletion suppresses basal expression of VCAM-1 in
murine endothelium
To determine if P2Y2R signaling is responsible for the high levels of
VCAM-1 expression in the lesion-prone aortic arch,we examined the ef-
fects of P2Y2R gene deletion on VCAM-1 expression. Real time-PCR re-
vealed a striking decrease in VCAM-1 mRNA levels in the aortic sinus
of P2Y2R−/−mice as compared towild-typemice (Fig. 3A). Remarkably,
ECs in the aortic sinus of P2Y2R−/− exhibited no detectable VCAM-1
immuno-staining (Fig. 3B). The complete lack of VCAM1 expression
suggests P2Y2R plays a dominant role in VCAM1 expression in the endo-
thelial cells of the aortic sinus.Fig. 2.High P2Y2R expression in the inner curvature of the aortic arch inwild-typemice. A–B, re
areas of the aortic sinus and descending thoracic aorta represented in the schematic. Endothelia
visual ﬁelds from 4 different mice.3.3. Nucleotide-dependent transcriptional regulation of the VCAM-1 gene is
mediated by P2Y2 receptor
We previously reported that P2Y2R activation increased expression of
VCAM-1 [8,21]. To explore themechanismof nucleotide-induced upregu-
lation of VCAM-1, we examined the effect of U UTPγS documented.
A plasmid containing a luciferase reporter gene driven by a murine
VCAM-1 promoter segment [17] was used to examine the effect of
the P2Y2R agonist UTPγS on VCAM-1 promoter activity. Aortic sinus
endothelial cells were transiently transfected with the pGL3- VCAM-1 lu-
ciferase reporter gene. As shown in Fig. 4, UTPγS induced a dose-
dependent stimulation of reporter gene activity, with maximal induction
occurring at a concentration of 10−3mol/L (Fig. 4). In contrast, UTPγS has
no such effect on VCAM-1 promoter activity in P2Y2R−/− ECs (Fig. 4).
These data indicate that P2Y2R regulates transcription of VCAM-1 in ECs.
3.4. P2Y2 receptor deﬁciency prevents fatty streak formation in ApoE−/−mice
Because endothelial cell surface expression of VCAM-1 is one of the
initial steps in the pathogenesis of atherosclerosis, we asked whether
P2Y2Rmay contribute to atherosclerosis disease onset. To do thiswe ex-
amined the developmental of early atherosclerosis in ApoE−/− and
ApoE−/−/P2Y2R−/−mice fed a standard chow diet for 15 weeks. There
was no statistical differences in body weight or plasma lipid proﬁlespresentative en face images and quantitative histograms of P2Y2R-positive cells in different
l cell nuclei and P2Y2R are in blue and green, respectively. Scale bar, 20 μm. P b 0.05. n=15
Fig. 3. Effect of P2Y2R gene deletion on VCAM-1 in different regions of the mouse aorta. A, Real-time PCR analysis of VCAM-1 mRNA levels in the aortic sinus of wild-type (n= 4) and
P2Y2R−/− (n= 3) mice. P b 0.05. B, representative en face immunostaining for VCAM-1 expression in the arch and descending thoracic aorta in P2Y2R−/−mice. No VCAM-1-positive
cell was detected in either part of the aorta. Endothelial cell nuclei are in shown blue. Scale bar, 20 μm. P b 0.05. n= 15 visual ﬁelds from 4 different mice.
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revealed the presence of characteristic fatty streak lesions in ApoE−/−
mice, as previously deﬁned [16] (Fig. 5A; Table 2). Fatty streak lesionsFig. 4. VCAM-1 promoter reporter assay. Luciferase activity in endothelial cells transfectedwith
bars represent standard error of mean from triplicates. P b 0.05.were observed in all ApoE−/−mice examined (n = 12) and consisted
of a mixture of macrophages and a few smoothmuscle cells with depo-
sition of connective tissue matrix (Fig. 5A). We observed strong.a pGL3 vector containingmurine VCAM-1 promoter and stimulatedwith UTP-γ-S. T Error
Table 1
Body weight and plasma lipid analysis in chow-fed ApoE−/− and ApoE−/−/P2Y2R−/−
mice.
Week 15 (n= 12) ApoE−/− ApoE−/−/P2Y2R−/−
Body weight (g) 28.5 ± 0.6 31.2 ± 0.5
Total Cholesterol (mg/dl) 409 ± 32 388 ± 25
Triglycerides (mg/dl) 58 ± 6 63 ± 8
16 S. Qian et al. / Vascular Pharmacology 85 (2016) 11–20VCAM-1 immunoreactivity in the intima and underlying media
layer (Fig. 5A-D). Cross sections of aortic sinus specimens stained with
Oil-red-O showed a mean lesion area of 0.06 mm2 ± 0.005 in these
ApoE−/− mice (Fig. 5B, p b 0.05). By comparison, only 25% of the
ApoE−/−/P2Y2R−/−mice (3/12 animals) exhibited any type of athero-
sclerotic lesion in the aortic sinus (Fig. 5A; Table 2). Moreover the le-
sions that formed were more immature and characterized by havingFig. 5. Analysis of atherosclerotic lesions in the aortic sinus of male ApoE−/− and ApoE−/−/P2Y
stainedwithMasson's trichrome for gross morphological analysis and classiﬁcation of lesions a
area was calculated by dividing the lesion area by the total cross-sectional area. D, Represent
Adjacent sections were stained with, Mac-3 antibody, VCAM-1 and smooth muscle α-actin anless than 10 foam cells/cross section (Table 2). As expected, normal
C57BL/6 mice did not develop any intimal lesions (Fig. 5A). Further ex-
amination of sections collected at every 100 μm over a 1-mm segment
from the beginning of the aortic root showed no evidence of lesion for-
mation in the descending aortic arch, thus ruling out the possibility that
P2Y2R deﬁciency results in atherosclerosis onset at an alternative site at
the aortic root. Theseﬁndings demonstrate that loss of P2Y2R attenuates
atherosclerosis development in ApoE−/− mice and prevents the forma-
tion of fatty streaks.
3.5. Inhibition of systemic production of LTα in ApoE−/− mice lacking the
P2Y2 receptor gene
In addition to promoting VCAM-1 expression, P2Y2R activation in-
duces expression and secretion of the inﬂammatory cytokine LTα in
mouse peritoneal macrophages [13]. We thus asked whether P2Y2R2R−/− littermate mice fed standard chow diet for 15 weeks. A, Aortic sinus cross sections
s shown in Table 2. B\\C, Cross sections were stainedwith Oil Red O and the relative lesion
ative images of immunohistological staining of atherosclerotic lesions in the aortic sinus.
tibodies, respectively. Each scale bar represents 100 μm.
Table 2
Classiﬁcation of atherosclerotic lesions in chow-fed ApoE−/− and ApoE−/−/P2Y2R−/−
mice.
Standard
diet (n= 12) (n= 12) ApoE−/− ApoE−/−/P2Y2R−/−
No lesion – 9 No foam cell
Category 1
formation
– 3 Early foam cell
Category 2 12 – Regular fatty streaks
Category 3 – – Mild plaque
Category 4 – – Moderate plaque
Category 5 – – Severe plaque
Sinus aortic lesions were classiﬁed into the following categories as previously described
[16]. (1) Early foam cell formation: up to 10 foamcell per section are present in the intima;
(2) regular fatty streaks: N10 cells present in the intima; (3) mild plaque: extension
of foam cells into the media: (4) moderate plaque: foam cells in the media, ﬁbrosis,
cholesterol clefts, mineralization and/or necrosis of the media; (5) severe plaque: similar
to category 4 but more extensive and deeper into the media.
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used to measure LTα and TNF-α plasma levels of individual standard
chow-fed mice at 4 weeks of age (baseline) and 15 weeks. The mean
plasma cytokine levels measured in the same mice at both time points
are summarized in Table 3. The mean plasma levels of TNF-α in
ApoE−/− and ApoE−/−/P2Y2R−/− groups were similar at baseline and
similarly increased at 15 weeks (n = 8 mice/genotype, P b 0.05).
ApoE−/− mice exhibited low LTα plasma concentrations at baseline,
which increased signiﬁcantly after 15 weeks whereas LTα was not de-
tectable either at baseline or after 15 weeks in ApoE−/−/P2Y2R−/−
mice. Further examination of plasma levels of inﬂammatory cytokines
using a Multiplex assay showed the effect of P2Y2R deletion to be selec-
tive to LTα, as no signiﬁcant difference in the levels of 13 other cyto-
kines (including interleukin (IL)-2, IL-3, IL-4, IL-6, TNF-α and IFN-γ)
was observed between ApoE−/− and ApoE−/−/P2Y2R−/− mice (Data
not shown).3.6. P2Y2 receptor deﬁciency impairs T cell-mediated LTα production in
ApoE−/−mice
As LTα is synthesized predominantly by T-cells [14], the ability of
P2Y2R to regulate LTα and TNF- α production was investigated in
CD4+ T cells activatedwith anti-CD3mAb. Cytokine levels in the culture
supernatants were measured after 1, 2, and 3 days using an ELISA. We
found that ApoE−/− CD4+ T cells released high levels of LTα and the
maximal levels were observed at 3 days post stimulation (Fig. 6A). By
comparison, LTα production was notably inhibited in CD4+T cells of
ApoE−/−/P2Y2R−/−mice (Fig. 6A). In contrast, although TNF-α produc-
tion in ApoE−/− CD4+ T cells occurred as early as 12 h after stimulation
and reached its highest level after 48 h (Fig. 6), the timing and amount
of secreted TNF-α were similar between CD4+ T cells in ApoE−/− and
ApoE−/−/P2Y2R−/−mice. CD4+ T cell TNF-αmRNA expression after 5,
10, or 24 h of activation also showed no difference between the two
genotypes whereas LTαmRNA levels in ApoE−/−/P2Y2R−/− CD4+ T ac-
tivated cells remained very low even after 24 h as compared to those in
CD4+ T cells from ApoE−/−mice (Fig. 6B, p b 0.05).Table 3




4 weeks 6.1 ± 0.7 (n= 12) 6.5 ± 0.5 (n= 10
15 weeks 9.3 ± 1.5 (n= 11) 8.9 ± 0.9 (n= 10
P b 0.01.3.7. Preventive treatment with TNFR1:Fc protects mice against fatty streak
lesions
As demonstrated above (Table 2 and Fig. 6), loss of P2Y2R did not
affect systemic TNF-α levels or TNF-α produced by activated CD4+
T cells, suggesting that LTα but not TNF-αmediates the inﬂammatory
processes associated with P2Y2R activation. We next asked whether
neutralization of LTα before the time of disease onset protects against
atherosclerosis.
Recombinant TNFR1:Fc, constructed by linkage of the cDNA
encoding this protein with a DNA fragment encoding the Fc region of
human IgG1, binds TNF-α and LT-αwith high afﬁnity and acts as antag-
onist of TNF-α and LT-α both in vitro and in vivo assays [22]. Prelimi-
nary experiments were conducted to assess the effects of increasing
doses of TNFR1:Fc protein on systemic LT-α levels. We found a
TNFR1:Fc dose of 100 μg per mouse to be highly effective in clearing
LT-α in the blood (Data not shown). Based on these results, ApoE−/−
mice were injected with 100 μg of TNFR1:Fc or isotype-matched
human irrelevant IgG control by IP once a day for 5 consecutive days
at 5 weeks of age. Mortality, body weight, serum concentrations of
total cholesterol, HDL and LDL cholesterol and triglycerides did not dif-
fer on the day of sacriﬁce (15 weeks of age) between the two groups.
(Table 4). Similarly, examination of blood parameters showed no statis-
tical differences in blood leukocyte, lymphocyte, platelet, or erythrocyte
counts between treatments (Table 4). Remarkably, none of the
TNFR1:Fc-treated mice exhibited any type of atherosclerotic lesion
(n = 8) (Fig. 7). No signiﬁcant difference in the atherosclerotic lesions
was found between the animals injected with human IgG or PBS (Data
not shown).4. Discussion
In the present study, we report that deletion of the P2Y2R genemod-
ulates inﬂammatory processes pivotal to the early stages of develop-
ment of atherosclerosis, thus limiting atherosclerotic plaque formation
in ApoE mice. Mechanistically, inhibition of the atherosclerotic lesion
may be caused by the repression of endothelial cell activation as moni-
tored by VCAM-1 expression. The absence of P2Y2R results in the selec-
tive loss of the cytokine LTα. The importance of attenuated LTα in this
process was further shown by the inhibition of fatty streak formation
that was observed following short-term treatment with the LTα/TNF
antagonist. Of signiﬁcance, this effectwas achievedwhen anti-LTα ther-
apy was initiated before any obvious sign of intimal accumulation of
foam cells.
Nucleotide release occurs in response to both physiological and
pathological stimuli [23–24]. We previously reported that nucleotide-
induced activation of P2Y2Rs contributes to monocyte recruitment
in vivo [7]. We further provided mechanistic insights into these obser-
vations by showing that binding of extracellular nucleotides to the
P2Y2R stimulates endothelial VCAM-1 expression and promotes the ad-
herence of monocyte to ECs [20]. VCAM-1 is particularly important for
ﬁrm, integrin-mediated adhesion of leukocytes to endothelial cells and
their subsequent trans-endothelial migration [6] an important early
step in the development of atherosclerosis. P2Y2R activation was
found to stimulate transcription of VCAM through activation of itsLtα
/− ApoE−/− ApoE−/−/P2Y2R−/−
) 3.7 ± 0.8 (n= 12) n.d
) 7.9 ± 1.8 (n= 12) n.d
Fig. 6. Time course of LTα, and TNF-α production in activated CD4+ T cells. A, CD4+ T cells were stimulatedwith anti-CD3mAb, and the culture supernatants were collected after 1, 2, and
3 days for cytokinemeasurement. Data shown aremean± SEM of 4 experiments, P b 0.05. B, CD4+ T cells were stimulatedwith anti-CD3mAb and collected at the indicated time periods.
Total RNA was extracted and subjected to Real-time PCR for the detection of LTα, and TNF-αmRNAs. Cytokine mRNA levels were quantiﬁed by densitometric analysis.
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VCAM-1 promoter in a P2Y2R dependent manner as UTP-γ-S failed to
activate the VCAM-1 promoter in ECs from P2Y2R−/−mice. Interesting-
ly, we observed that P2Y2R is differentially expressed in the mouse
aorta, being most highly expressed in the aortic sinus where VCAM-1
is also preferentially expressed. These ﬁndings provide mechanistic in-
sights that help explain why the aortic sinus is particularly susceptible
to the development of atherosclerotic plaque. Because of the impor-
tance VCAM-1 in the early stages of atherosclerosis [6], we postulated
that deletion of the P2Y2R gene could delay fatty streak formation.
When maintained on a regular chow diet, within 15 weeks ApoE−/−
mice developed fatty streak lesions mainly comprised of macrophages
and a few SMCs (Fig. 5, Table 2). In contrast, deletion of P2Y2R sup-
pressed basal expression of VCAM-1 in the aortic sinus and attenuated
both lesion development and maturation (Fig. 5, Table 2). In addition
to decreased VCAM-1 expression, we also found that P2Y2R deﬁciency
in ApoE−/−mice, led to a striking decrease in the plasma levels of the
pro-inﬂammatory cytokine LTα. The effect of P2Y2R deletion was selec-
tive to LTα, as no signiﬁcant difference in the levels of other examined
cytokines was observed between ApoE−/− and ApoE−/−/P2Y2R−/−
mice. Unlike TNFα, which is produced by a large variety of cells, includ-
ing non-lymphoid cells, production of LTα is restricted to lymphocytes
and, to a lesser extent, NK cells and B cells [14,25]. We showed that
the levels of LTα released by activated ApoE−/−CD4+ T cells were
very signiﬁcant and appear to be much higher than those of TNF-α.
ApoE−/−/P2Y2R−/− CD4+ T cells produced very low levels of LTα com-
pared to ApoE−/− CD4+ T cells, whereas TNF-α levels and its time
course of release were similar in both groups of T cells. The selective at-
tenuation of LTα but not TNFα signal in T lymphocytes from P2Y2R-Table 4




(n= 15) ± SD
IgG-treatment
(n= 10) ± SD P value
Leukocytes (/nl) 3.08 ± 0.59 3.63 ± 0.39 n.s.
Erythrocytes (/pl) 7.72 ± 1.09 7.11 ± 0.84 n.s.
Triglycerides (mg/dl) 101.67 ± 38.87 78.50 ± 24.04 n.s.
Total cholesterol (mg/dl) 344.44 ± 54.94 365.33 ± 36.20 n.s.
Body weight (g) 28.80 ± 2.40 29.30 ± 2.10 n.s.deﬁcient mice suggests that P2Y2R may be involved in T-cell receptor
(TCR)-dependent T cell activation. There is evidence that P2 receptor-
mediated signaling is involved in TCR-dependent T cell activation.
Murine T cell activation by stimulation of TCR results in both CD25
expression and interleukin (IL)-2 production. However, the P2Y6 antag-
onist MRS2578 signiﬁcantly blocked the increases of both CD25 expres-
sion and IL-2 production, and P2X7 antagonists A438079 and oxidized
ATP inhibited IL-2 production rather than CD25 expression, suggesting
the involvement of P2Y6 and P2X7 receptors in different processes of
T cell activation [26].
Our results strongly suggest that decrease in LTα production is likely
contributing to the attenuated atherosclerosis observed in ApoE−/−/
P2Y2R−/− mice. In further support of this, LTα/TNF antagonism was
found to attenuate atherosclerosis development in ApoE−/− mice
(Fig. 7). Recombinant TNFR1:Fc, a chimeric protein comprised of the li-
gand binding portion of TNFR1 fused to the Fc region of human IgG1,
binds TNF and LTα with high afﬁnity and acts as an antagonist of TNF
and LTα both in vitro and in vivo [22]. TNFR1:Fc is a potent inhibitor
of arthritis, administration of this cytokine antagonist over brief periods
causes sustained amelioration of disease incidence and severity [22].
Notably, etanercept, a dual TNF-α and LT-α inhibitor, has proven to be
very efﬁcient against rheumatoid arthritis [27]. Aswe found that soluble
TNFR1:Fc administration efﬁciently blocked fatty streak formation in
ApoE−/−mice, which are predisposed to atherosclerosis, this presents
the exciting possibility that TNFR1:Fc may be an effective preventative
therapy for patients at high risk of developing atherosclerosis. Further-
more, preliminary observations (not shown) indicate that TNFR1:Fc
treatment caused a signiﬁcant decrease in both membrane and plasma
levels of VCAM-1 suggesting that TNFR1:Fc exerts its action at least in
part through downregulation of VCAM-1, thus blocking monocyte/
macrophage recruitment. These data suggest that P2Y2R, regulate
VCAM-1 expression both directly via regulating its promoter activity
and indirectly through regulating LTα expression or secretion. Further
support for a role in LTα in atherosclerosis is provided by previous stud-
ies which showed that a single nucleotide polymorphism (SNP) in the
galectin gene that is required for LTα secretion is associated with sus-
ceptibility to myocardial infarction [15]. However, the relevance of
these SNPs to the pathogenesis of myocardial infarction is controversial
[28]. Our data reveal a new pathway whereby P2Y2R activation regu-
lates LTα secretion, suggesting that mechanisms other than SNPs in
the galectin-2 gene control LTα secretion in vivo.
Fig. 7. Effect of TNFR1:Fc on the development of atherosclerosis in ApoE−/− mice.
TNFR1:Fc or human IgG1 was administered (100 μg/mouse for 5 consecutive days) to
5 week-old ApoE−/−mice fed a standard chow diet. Mice were sacriﬁced at 15 weeks of
age. A, Aortic sinus cross sections were stained with Masson's trichrome for gross
morphological evaluation. B\\C, Cross sections were stained with Oil Red O and the
relative lesion area was then quantiﬁed. P b 0.05 vs IgG-injected controls.
19S. Qian et al. / Vascular Pharmacology 85 (2016) 11–20The role of TNF in atherosclerosis is still unclear. Previous studies
have shown that deletion of the TNFα gene has no effect on the devel-
opment of atherosclerosis [29]. However, subsequent studies concluded
that inhibition of TNα reduce atherosclerotic lesions in ApoE−/−mice
[30]. LTα and TNFα genes are clustered within 12 kb of genomic DNA
inside of the major histocompatibility complex [31]. Indeed, impaired
TNF production by LTα total knockout mice was previously reported
[32]. Unlike the conventional LTα−/−mice, LTαΔ/Δ animals generated
using Cre- LoxP technology are capable of producing normal levels of
systemic TNFα upon lipopolysaccharide challenge [33]. Therefore, is
likely that the close proximity between the two genes accounts for the
discrepancies in previous studies regarding the roles of LTα and TNF
in atherosclerosis [28–29]. However, our data clearly indicate that LTα
but not TNF-α mediates the inﬂammatory processes associated with
P2Y2R activation.In conclusion, this study supports the hypothesis that nucleotide
release during endothelial injury activates the P2Y2R, which triggers
production of the pro-inﬂammatory cytokine LTα and upregulates ex-
pression of VCAM-1, thus modulating inﬂammatory processes in the
early development of atherosclerosis. Anti-LTα treatment prevents ath-
erosclerosis by overriding detrimental inﬂammatory processes evoked
by P2Y2R activation. Our ﬁndings suggest that targeting this nucleotide
receptor could be an effective therapeutic approach in atherosclerosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.vph.2016.06.001.
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